Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
bTB cattle vaccine unlikely until 2023
Cattle vaccine at least ten years away, says EC

The European Commission (EC) has told Defra that a cattle vaccine for bovine TB (bTB) is unlikely to be made commercially available until 2023.

Writing to Defra secretary Owen Paterson, EU health commissioner Tonio Borg said a cattle vaccination against bTB is "explicitly forbidden," according to EU legislation on disease control. The ban, he said is due to the fact that vaccination interferes with the TB skin test. This means that vaccinated animals who become infected cannot be distinguished from uninfected vaccinated animals. "This would jeopardise current bTB control and eradication policy," he said.

According to Mr Borg, "many knowledge gaps" exist regarding the performance of the the live BCG vaccine, which is currently the only available candidate. He said a recent vaccination workshop in Cardiff indicated a lack of knowledge on the safety of the vaccine, its conditions for use and the suitability of a DIVA test to distinguish between infected and uninfected vaccinated animals.

Mr Borg continued to say that the "fundamental scientific information" required to change EU policy on cattle vaccination, accompanied by a DIVA test was not yet available. Before a vaccine can be made commercially available, he added, further study is required to address food safety issues, such as the shedding of vaccine strain in milk. There are human health concerns as BCG is currently the only vaccine available for humans. It is possible, Mr Borg said, that its use in cattle could lead to BCG-resistant strains of bTB that may also affect humans.

He outlined in his letter a "tentative timeline for bTB vaccination of cattle in the UK," which suggests possible changes to EU legislation is at least ten years away.

Mr Paterson said Mr Borg's letter "recognises that we are on course to deploy a vaccine. The legal and scientific process could take up to 10 years. In the meantime we will continue to use all the tools at our disposal."

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.